Carbon nanoparticles versus patent blue dye for detection of sentinel lymph node in patients with early breast cancer

被引:0
|
作者
Elsebaai, Mahmoud R. M. [1 ]
Shehab, Mohamed A. H. [1 ]
Hanafy, Dina M. [1 ]
Abd Al Moaty, Karim F. [1 ]
机构
[1] Ain Shams Univ, Fac Med, Gen Surg, 32 Mohamed Ibrahim, Cairo 11788, Egypt
来源
EGYPTIAN JOURNAL OF SURGERY | 2024年 / 43卷 / 02期
关键词
carbon nanoparticles; patent blue V dye; sentinel lymph nodes; QUALITY-OF-LIFE; BIOPSY; MULTICENTER; IDENTIFICATION; DISSECTION;
D O I
10.4103/ejs.ejs_311_23
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundSentinel lymph nodes biopsy (SLNB) has replaced axillary lymph node dissection (ALND) in a considerable percentage of patients with early-stage breast cancer which was a great advance in preventing many surgical complications and enhancing their health welfare. Although there are different sentinel lymph nodes (SLNs) tracers with different identification rates, there is no agreement about the idealistic method.AimThe study was designed to compare carbon nanoparticles and patent blue v dye regarding SLNs detection rate, number of SLNs, time of detection, metastatic SLNs, cost, and safety in patients with early breast cancer and clinically node-negative axilla.Patients and methodsA total of 40 patients with axillary lymph node-negative early-stage breast cancer patients were divided into two groups and subjected to carbon nanoparticles and patent blue V dye in group A and group B, respectively. Patients who were pregnant or lactating had node-positive axilla (N1-3) or metastatic breast cancer (M1) or had neoadjuvant chemotherapy were excluded.ResultsThe mean age was 48.3 +/- 9.5 and 47 +/- 8.9, while the mean BMI of 33.3 +/- 4.8 and 32.834 +/- 4.862, the SLN detection rates were 95% and 90% in groups A and B, respectively. A total of 128 sentinel lymph nodes (SLNs) were removed from patients in the two groups (65 with Carbon Nanoparticles and 63 with patent blue dye). The mean number of SLNs was 3.4 +/- 0.7 (range, 2-5) and 3.5 +/- 1.2 (range, 2-7), mean time of SLNs detection was 13.5 +/- 4.5 (range, 7-22) and 12.7 +/- 3.6 (range, 7-18 min) between group A and B, respectively.ConclusionThere is no significant difference between carbon nanoparticles and patent blue dye regarding axillary SLNs in early breast cancer regarding identification rate, number of SLNs, time of detection, metastatic SLNs, cost, and safety with slight preference to carbon nanoparticles regarding postoperative skin staining and Egyptian market availability.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [1] Sentinel Lymph Node Detection Using Carbon Nanoparticles in Patients with Early Breast Cancer
    Wu, Xiufeng
    Lin, Qingzhong
    Chen, Gang
    Lu, Jianping
    Zeng, Yi
    Chen, Xia
    Yan, Jun
    PLOS ONE, 2015, 10 (08):
  • [2] Use of Fluorescence Imaging in Combination with Patent Blue Dye versus Patent Blue Dye Alone in Sentinel Lymph Node Biopsy in Breast Cancer
    Tong, Meng
    Guo, Wenbin
    Gao, Wei
    JOURNAL OF BREAST CANCER, 2014, 17 (03) : 250 - 255
  • [3] Anaphylaxis to patent blue dye during sentinel lymph node biopsy for breast cancer
    Mullan, MH
    Deacock, SJ
    Quiney, NF
    Kissin, MW
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2001, 27 (02): : 218 - 219
  • [4] Reliability of patent blue dye use in detection of sentinel lymph node in lung cancer
    Bohanes, T
    Klein, J
    Neoral, C
    Szkorupa, M
    LUNG CANCER, 2005, 49 : S103 - S103
  • [5] Patent Blue Dye and An Atypical Anaphylactic Reaction After Sentinel Lymph Node Biopsy in Early Breast Cancer
    Dang, Yen
    Engel, Jay
    BREAST JOURNAL, 2012, 18 (01): : 91 - 92
  • [6] Sentinel lymph node detection for breast cancer:: Which patients are best suited for the patent blue dye only method of identification?
    Nos, C
    Fréneaux, P
    Guilbert, S
    Falcou, MC
    Salmon, RJ
    Clough, KB
    ANNALS OF SURGICAL ONCOLOGY, 2001, 8 (05) : 438 - 443
  • [7] Sentinel lymph node detection for breast cancer: Which patients are best suited for the patent blue dye only method of identification?
    Nos C.
    Fréneaux P.
    Guilbert S.
    Falcou M.C.
    Salmon R.J.
    Clough K.B.
    Annals of Surgical Oncology, 2001, 8 (5) : 438 - 443
  • [8] Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer
    Radovanovic, Z
    Golubovic, A
    Plzak, A
    Stojijkovic, B
    Radovanovic, D
    EJSO, 2004, 30 (09): : 913 - 917
  • [9] Sentinel lymph node identification by patent blue dye in breast cancer: Experience of the Institut Curie
    Nos, C
    Bourgeois, D
    Zafrani, B
    Salmon, RJ
    Sastre, X
    Clough, KB
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (04): : S95 - S95
  • [10] Sentinel lymph node mapping with patent blue dye in patients with breast cancer: a retrospective single institution study
    Olivier, Fabrice
    Courtois, Audrey
    Jossa, Veronique
    Bruck, Gaelle
    Aouachria, Samy
    Coibion, Michel
    Jerusalem, Guy
    GLAND SURGERY, 2021, 10 (09) : 2500 - 2507